Abstract: Objects to be achieved are to provide a nerve cell with which it is possible to visualize and quantify the intracellular tau without using the exogenous promoter and to provide a pluripotent stem cell with which the nerve cell can be produced, to provide a method of screening a substance, including using the pluripotent stem cell or nerve cell described above, and a substance screened by the above method, and to provide a kit including a targeting vector and a gRNA. There is provided a pluripotent stem cell including a DNA encoding a reporter molecule, the DNA being introduced adjacent to an endogenous tau gene such that a tau protein is expressed as a fusion protein fused with a reporter molecule.

Abstract: An object of the present invention is to provide a nerve cell in which tau aggregation and cell death are caused; a screening kit and a screening method, in which the nerve cell is used; a drug candidate substance obtained by the screening method; a human pluripotent stem cell for producing the nerve cell; and a method of producing the nerve cell. There is provided a nerve cell having an introduced exogenous wild-type tau gene.

Abstract: The present invention provides a method for producing human A1 astrocytes, which includes inducing human A1 astrocytes from human astrocytes other than human A1 astrocytes; human A1 astrocytes obtained by the method for producing human A1 astrocytes; and a method for evaluating a test substance, which uses the human A1 astrocytes described above. According to the present invention, there is provided the method for producing human A1 astrocytes, which includes a step a of culturing human astrocytes other than human A1 astrocytes in the presence of TNF? and IFN?.

Abstract: Provided is a method for obtaining base sequence information of a single cell derived from a vertebrate, by which PCR amplification of an objective region can be performed uniformly and accurately.